MA50675A - Inhibiteurs de la creb binding protein (cbp) - Google Patents

Inhibiteurs de la creb binding protein (cbp)

Info

Publication number
MA50675A
MA50675A MA050675A MA50675A MA50675A MA 50675 A MA50675 A MA 50675A MA 050675 A MA050675 A MA 050675A MA 50675 A MA50675 A MA 50675A MA 50675 A MA50675 A MA 50675A
Authority
MA
Morocco
Prior art keywords
cbp
inhibitors
binding protein
creb binding
creb
Prior art date
Application number
MA050675A
Other languages
English (en)
Other versions
MA50675B1 (fr
Inventor
Jennifer R Downing
Anna Ericsson
Bradford Graves
Torsten Herbertz
Hongbin Li
Steven Mischke
Shawn E R Schiller
Angela V West
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051214 external-priority patent/WO2019055869A1/fr
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MA50675A publication Critical patent/MA50675A/fr
Publication of MA50675B1 publication Critical patent/MA50675B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA50675A 2018-06-29 2019-07-01 Inhibiteurs de la creb binding protein (cbp) MA50675B1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051214 WO2019055869A1 (fr) 2017-09-15 2018-09-14 Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
PCT/US2018/051235 WO2019055877A1 (fr) 2017-09-15 2018-09-14 Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
US201962819490P 2019-03-15 2019-03-15
PCT/US2019/039936 WO2020006483A1 (fr) 2018-06-29 2019-06-28 Inhibition de la protéine de liaison à creb (cbp)
US16/457,596 US10870648B2 (en) 2018-06-29 2019-06-28 Inhibiting CREB binding protein (CBP)

Publications (2)

Publication Number Publication Date
MA50675A true MA50675A (fr) 2021-04-07
MA50675B1 MA50675B1 (fr) 2021-09-30

Family

ID=68987627

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50675A MA50675B1 (fr) 2018-06-29 2019-07-01 Inhibiteurs de la creb binding protein (cbp)

Country Status (26)

Country Link
US (3) US10870648B2 (fr)
EP (1) EP3998266A1 (fr)
JP (4) JP6781806B2 (fr)
KR (2) KR102805503B1 (fr)
CN (2) CN112513038B (fr)
AU (3) AU2019295790B2 (fr)
BR (1) BR112020026783A2 (fr)
CA (1) CA3105099A1 (fr)
CY (1) CY1124762T1 (fr)
DK (1) DK3587418T3 (fr)
ES (1) ES2900105T3 (fr)
HR (1) HRP20211698T1 (fr)
HU (1) HUE056885T2 (fr)
IL (3) IL279734B2 (fr)
LT (1) LT3587418T (fr)
MA (1) MA50675B1 (fr)
MX (2) MX2020014303A (fr)
PL (1) PL3587418T3 (fr)
PT (1) PT3587418T (fr)
RS (1) RS62732B1 (fr)
SA (1) SA520420909B1 (fr)
SG (1) SG11202012767UA (fr)
SI (1) SI3587418T1 (fr)
SM (1) SMT202100636T1 (fr)
WO (1) WO2020006483A1 (fr)
ZA (2) ZA202100509B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
CN113784967B (zh) * 2019-03-15 2024-07-26 福马治疗股份有限公司 用于治疗雄激素受体阳性形式的癌症的组合物和方法
AU2021298154A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
EP4171556A1 (fr) 2020-06-25 2023-05-03 Tolremo Therapeutics AG Combinaison d'un inhibiteur de bromodomaine cbp/p300 et d'un inhibiteur d'egfr pour une utilisation dans le traitement de nsclc mutant egfr
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
WO2026090300A1 (fr) * 2024-10-23 2026-04-30 Foghorn Therapeutics Inc. Composés et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
WO1995020589A1 (fr) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Inhibiteurs de la signalisation cellulaire
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
EP1339812B1 (fr) 2000-11-20 2008-07-16 MERCK PATENT GmbH Composes photoisomerisables chiraux
CA2463136A1 (fr) 2001-10-17 2003-04-24 Raymond Andersen Modulateurs de ship 1
WO2003045929A1 (fr) 2001-11-26 2003-06-05 Takeda Chemical Industries, Ltd. Derive bicyclique, procede de production de ce derive et utilisation correspondante
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (fr) 2003-11-13 2008-10-06
WO2005066162A1 (fr) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Composes synthetiques et derives de ceux-ci en tant que modulateurs de fumee ou d'ingestion de nicotine et du cancer du poumon
JP4790703B2 (ja) 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
JP2009520038A (ja) 2005-12-19 2009-05-21 ジェネンテック・インコーポレーテッド ピリミジンキナーゼインヒビター
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
AU2007249827A1 (en) 2006-05-09 2007-11-22 Colorado State University Research Foundation Methods for treating blood disorders
EP1878724A1 (fr) 2006-07-15 2008-01-16 sanofi-aventis Synthèse régiosélective des benzimidazoles et azabenzimidazoles catalysée par le palladium
CA2574531C (fr) 2007-01-19 2016-10-25 The University Of British Columbia Promoteurs de l'acetylation d'hat et utilisations de compositions contenant ceux-ci pour promouvoir l'immunogenicite
WO2008157680A2 (fr) 2007-06-21 2008-12-24 The Wistar Institute Procédés et compositions servant à moduler l'activité de la p300/cbp
WO2009000413A1 (fr) 2007-06-26 2008-12-31 Sanofi-Aventis Synthèse régiosélective catalysée par le cuivre de benzimidazoles et d'azabenzimidazoles
JP5223864B2 (ja) 2007-06-27 2013-06-26 大正製薬株式会社 11β−HSD1阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
WO2010110380A1 (fr) * 2009-03-27 2010-09-30 興和株式会社 Composé de pipéridine condensé et agent pharmaceutique le contenant
WO2010118208A1 (fr) 2009-04-09 2010-10-14 Exelixis, Inc. Dérivés benzoxazepin-4-(5h)-yle et leur utilisation pour traiter le cancer
AU2010237633B2 (en) 2009-04-15 2015-09-17 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010138490A1 (fr) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazèpines comme inhibiteurs de mtor et méthodes d'utilisation et de fabrication
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
CA2791738C (fr) 2010-03-01 2020-06-09 Gtx, Inc. Composes d'aryl imidazolyl destines au traitement du cancer
WO2011150156A2 (fr) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Composés hétéroarylés et leurs procédés d'utilisation
WO2012019093A1 (fr) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Composés synthétiques et procédés pour diminuer l'auto-administration de nicotine
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
US9295754B2 (en) 2011-02-24 2016-03-29 Emory University Noggin inhibitory compositions for ossification and methods related thereto
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (fr) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. Inhibiteurs de p300/cbp et leurs méthodes d'utilisation
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
WO2014045305A1 (fr) 2012-09-21 2014-03-27 Advinus Therapeutics Limited Composés tricycliques condensés substitués, compositions et applications médicales correspondantes
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
CN105473581B (zh) 2013-06-21 2019-04-23 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的新取代的双环化合物
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
UY35834A (es) 2013-11-14 2015-05-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN107073125A (zh) 2014-09-19 2017-08-18 基因泰克公司 Cbp/ep300和bet抑制剂用于治疗癌症的用途
EP3632915A1 (fr) 2014-11-27 2020-04-08 Genentech, Inc. Composés 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine utilisés comme inhibiteurs de cbp et/ou de ep300
US10435402B2 (en) 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (fr) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Composés bicycliques, compositions et applications médicinales correspondantes
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
CN109414596B (zh) 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
WO2017205536A2 (fr) 2016-05-24 2017-11-30 Genentech, Inc. Composés thérapeutiques et leurs utilisations
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
WO2019055877A1 (fr) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)

Also Published As

Publication number Publication date
US20220162207A1 (en) 2022-05-26
IL321337A (en) 2025-08-01
PT3587418T (pt) 2021-12-02
JP2020002135A (ja) 2020-01-09
IL279734B1 (en) 2024-07-01
JP2021042255A (ja) 2021-03-18
MX2020014303A (es) 2021-03-25
AU2023226653B2 (en) 2025-09-04
DK3587418T3 (da) 2021-10-11
SG11202012767UA (en) 2021-01-28
SA520420909B1 (ar) 2024-11-12
JP2025094157A (ja) 2025-06-24
CN116178369A (zh) 2023-05-30
IL279734B2 (en) 2024-11-01
CA3105099A1 (fr) 2020-01-02
MX2023013508A (es) 2023-12-13
IL313466A (en) 2024-08-01
JP2020128426A (ja) 2020-08-27
CN112513038A (zh) 2021-03-16
CN112513038B (zh) 2023-01-10
IL279734A (en) 2021-03-01
MA50675B1 (fr) 2021-09-30
AU2019295790B2 (en) 2023-07-13
US11254674B2 (en) 2022-02-22
ZA202210560B (en) 2025-12-17
EP3998266A1 (fr) 2022-05-18
US12378242B2 (en) 2025-08-05
US20200299295A1 (en) 2020-09-24
US20200002332A1 (en) 2020-01-02
SI3587418T1 (sl) 2022-03-31
PL3587418T3 (pl) 2022-02-21
WO2020006483A1 (fr) 2020-01-02
KR20250067962A (ko) 2025-05-15
US10870648B2 (en) 2020-12-22
IL313466B2 (en) 2025-11-01
CY1124762T1 (el) 2022-07-22
ZA202100509B (en) 2022-12-21
LT3587418T (lt) 2021-11-25
RS62732B1 (sr) 2022-01-31
JP7017801B2 (ja) 2022-02-09
JP6781806B2 (ja) 2020-11-04
KR102805503B1 (ko) 2025-05-09
KR20210025631A (ko) 2021-03-09
AU2019295790A1 (en) 2021-01-28
IL313466B1 (en) 2025-07-01
HRP20211698T1 (hr) 2022-02-18
AU2025210762A1 (en) 2025-08-21
BR112020026783A2 (pt) 2021-03-30
SMT202100636T1 (it) 2022-01-10
AU2023226653A1 (en) 2023-09-21
HUE056885T2 (hu) 2022-03-28
ES2900105T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
IL282179A (en) Protein tyrosine phosphatase inhibitors
IL286462A (en) Protein tyrosine phosphatase inhibitors
IL281962A (en) Il-12 heterodimeric fc-fusion proteins
EP3932338C0 (fr) Tourniquet
LT3587418T (lt) Creb surišančio baltymo (cbp) inhibitoriai
EP3630783A4 (fr) Inhibiteurs protéiques de liaison à la pénicilline
EP3630782A4 (fr) Inhibiteurs de protéines de liaison à la pénicilline
EP3621994A4 (fr) Protéines de liaison à la mésothéline
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
EP3833350A4 (fr) Inhibiteurs de pyrrolopyrimidine itk
EP3801503A4 (fr) Inhibiteurs de sarm1
IL284664A (en) Multispecific binding proteins
EP3802551A4 (fr) Inhibiteurs de protéine de liaison à la pénicilline
MA52813A (fr) Inhibiteurs de sarm1
MA52809A (fr) Inhibiteurs de sarm1
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3938358A4 (fr) Inhibiteurs de rad51
EP3661961A4 (fr) Anticorps se liant à l'alpha-synucléine active
DK3737402T5 (da) Modificeret protein
IL284317A (en) Pseudofab-based multispecific binding proteins
EP3555092A4 (fr) Inhibiteurs de protéine kinase
EP3765265A4 (fr) Agent liant
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3792200A4 (fr) Conteneur-citerne